What Is Semax? A Research Guide to the Nootropic Peptide

Semax is one of the few research peptides with actual regulatory approval, albeit not in the United States. Developed over several decades at the Institute of Molecular Genetics of the Russian Academy of Sciences, it has been approved in Russia and Ukraine for the treatment of ischemic stroke, cognitive disorders, and optic nerve disease.

That clinical pedigree makes Semax an unusual peptide to study. Unlike most compounds in the research peptide market, there is real-world clinical usage data to draw from, not just animal models. Here is what the research says.

---

What Is Semax?

Semax is a synthetic heptapeptide -- a chain of seven amino acids -- derived from the first four residues of adrenocorticotropic hormone (ACTH). Its full sequence is ACTH(4-7)-Pro-Gly-Pro, meaning it takes the 4-7 fragment of ACTH and adds a stabilizing Pro-Gly-Pro tail that extends its biological half-life.

Despite its ACTH origin, Semax does not stimulate the adrenal glands or affect cortisol levels. The ACTH(4-7) fragment retains neurotropic and nootropic properties while lacking the hormonal (steroidogenic) effects of full-length ACTH. This dissociation between cognitive and endocrine activity is a key feature of its pharmacological profile.

Semax is typically delivered intranasally as a 0.1% or 1% solution, which is the approved route in Russia.

View the full Semax research profile and compare vendor prices on PeptidePrices.

---

How Does Semax Work?

Semax operates through multiple neurobiological pathways, which is why researchers have found it difficult to classify into a single pharmacological category.

BDNF and neurotrophin upregulation. Semax potently increases the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in the hippocampus, as demonstrated in rat studies (Brain Research, 2006, PMID: 16996037; Journal of Molecular Neuroscience, 2010, PMID: 19662538). BDNF is one of the most important molecules in learning, memory formation, and neuronal survival.

Immune and vascular gene modulation. A genome-wide analysis in a focal ischemia (stroke) model found that Semax modulates the expression of over 84 genes involved in immune response and vascular function (BMC Genomics, 2014, PMID: 24661656). This broad transcriptomic effect explains its multi-system neuroprotective properties beyond simple neurotransmitter modulation.

Dopaminergic and serotonergic activity. Research suggests Semax influences dopamine and serotonin turnover in the brain, which may contribute to its observed effects on attention, motivation, and mood in clinical settings.

Enkephalinase inhibition. Semax has been reported to modulate endogenous opioid peptide metabolism by influencing enkephalin-degrading enzymes, potentially affecting pain perception and stress responses.

---

What Does the Research Say?

Ischemic stroke. Multiple clinical studies in Russia have evaluated Semax for acute ischemic stroke. A 2018 study in Zhurnal Nevrologii (PMID: 29798983) reported improvements in neurological outcomes when Semax was administered intranasally alongside standard stroke care. It is approved for this indication in Russia.

Cognitive enhancement. Semax has been studied in patients with cognitive disorders, including those arising from cerebrovascular disease. The Russian approval for cognitive disorders is based on clinical trial data showing improvements in memory, attention, and processing speed.

Neuroprotection. A 2020 review in the International Journal of Molecular Sciences (PMID: 32575851) catalogued the molecular-level protective properties of Semax, including its antioxidant effects, anti-inflammatory activity, and ability to reduce neuronal apoptosis under ischemic conditions.

ADHD-related research. The Alzheimer's Drug Discovery Foundation's review of Semax noted its potential relevance to attention disorders given its dopaminergic modulation, although formal ADHD trials have not been conducted.

Explore the complete citation set in the PeptidePrices research library.

---

Semax Safety Profile

PeptidePrices assigns Semax a safety rating of 7 out of 10. It is approved for neurological conditions in Russia and is administered intranasally, a non-invasive route. Clinical studies and post-marketing data from Russia report that it is well-tolerated with no major safety signals. Side effects reported in the literature are generally mild and infrequent.

The main limitation is the absence of large-scale Western regulatory review. The clinical data supporting its approval comes primarily from Russian and Ukrainian research institutions. While this research is peer-reviewed, it has not undergone FDA or EMA evaluation.

---

Semax vs. Similar Compounds

• Selank is another Russian-developed heptapeptide, but focused on anxiolysis (anxiety reduction) rather than cognition. Selank is derived from tuftsin (an immune peptide) while Semax is derived from ACTH. They are often discussed as complementary.
• Dihexa is a synthetic nootropic peptide targeting hepatocyte growth factor (HGF) signaling. Different mechanism, more potent in some in-vitro assays, but with far less clinical data than Semax.
• Cerebrolysin is a porcine brain-derived peptide mixture approved in several countries for stroke and dementia. More established clinically but involves a complex mixture rather than a single defined compound.
• Noopept (GVS-111) is a small-molecule nootropic often compared to Semax. Noopept works through AMPA and NMDA receptor modulation rather than BDNF upregulation.

Semax is distinctive for combining an established clinical approval history with a well-characterized mechanism centered on neurotrophin signaling.

---

Dosing in Research Settings

The following is for informational purposes only and does not constitute medical advice.

In its approved formulation in Russia, Semax is administered intranasally at a 0.1% solution (approximately 50 mcg per drop), with typical protocols involving 2-3 drops per nostril 2-3 times daily. A higher-concentration 1% formulation is used in acute neurological settings.

Because Semax is not FDA-approved, there are no Western clinical dosing guidelines. Any protocols discussed online are derived from Russian clinical practice or extrapolated from published studies.

---

Comparing Semax Prices

Semax pricing varies across vendors, partly because some sell it in nasal spray form while others sell lyophilized powder. These are different products with different preparation requirements, so per-milligram comparison is important.

PeptidePrices normalizes all vendor pricing to a per-milligram basis across 19+ tracked vendors.

See the live Semax price comparison across all vendors.

The AI Stack Builder can help you explore nootropic protocol combinations if you are researching Semax alongside other cognitive-focused compounds.

---

Wrapping Up

Semax is one of the more credentialed compounds in the research peptide space, backed by decades of Russian clinical use and an approval history for stroke and cognitive disorders. Its mechanism -- centered on BDNF upregulation and broad transcriptomic neuroprotection -- is well-characterized in published literature. Western clinical validation remains limited, but the existing evidence base is substantially deeper than what most research peptides can claim.

If you are researching Semax, review the published clinical data, understand the regulatory situation in your country, and compare vendor prices before purchasing.

Compare Semax prices across all vendors at PeptidePrices -- research smarter, spend less.

---

For research purposes only. Not for human consumption. Not medical advice. Always consult a qualified healthcare provider before making any health or supplementation decisions.